Brief: Histogen Announces Completion Of Dosing Milestone In 1B/2A Trial For Androgenic Alopecia In Men
10/09/2020 14:13
Sept 10 (Reuters) - Histogen Inc HSTO.O :
* HISTOGEN ANNOUNCES COMPLETION OF DOSING MILESTONE IN ITS
1B/2A
TRIAL FOR ANDROGENIC ALOPECIA IN MEN
* HISTOGEN INC - REMAIN ON TRACK TO ANNOUNCE TOP LINE DATA
RESULTS
IN Q4
Source text for Eikon: ID:nGNX36QL65
Further company coverage: HSTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Histogen
See all newsBrief: Histogen Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Histogen Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Histogen Announces Board Approval Of Complete Liquidation And Dissolution
Histogen Inc expected to post a loss of 90 cents a share - Earnings Preview
Histogen to explore strategic options, shares up